Comprehensive analysis of the role of PTGFRN as a new potential biomarker in lung adenocarcinoma

Lung adenocarcinoma, the most prevalent and heterogeneous subtype of lung cancer, presents significant challenges for diagnosis and treatment. Prostaglandin F2 receptor negative regulator (PTGFRN) has recently emerged as a molecule of interest in cancer, but its specific contribution to lung adenocarcinoma pathogenesis remains to be elucidated. This study employed bioinformatics methods to investigate the expression patterns and potential functional roles of PTGFRN in lung adenocarcinoma. We utilized large-scale transcriptome datasets from public repositories to analyze PTGFRN expression levels and prognostic significance in lung adenocarcinoma cohorts. Furthermore, we explored the correlation between PTGFRN and immune cell infiltration to elucidate the potential molecular mechanisms of PTGFRN dysregulation in lung cancer development. Overall, our findings provide insights into the significance of PTGFRN in lung adenocarcinoma pathogenesis and emphasize its potential as a novel biomarker and therapeutic target for precision medicine approaches.